Education
About Us
Working with TipRanks
Follow Us
Assertio Therapeutics Inc (ASRT)
NASDAQ:ASRT
Earnings Data
Report Date
Jul 31, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.08Last Year’s EPS
-0.04Same Quarter Last Year
Strong Buy
Based on 5 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 12, 2025
|% Change Since: 12.90%
|Next Earnings Date:Jul 31, 2025
Earnings Call Sentiment|Neutral
The earnings call presented a mix of positive developments like slight outperformance in net product sales and strategic legal settlements, but also highlighted challenges such as declines in Rolvedon, Indocin, and Sympazan sales, alongside increased SG&A expenses and reduced adjusted EBITDA.Company Guidance
During the Assertio Holdings First Quarter 2025 Results Conference Call, the company maintained its full-year guidance for net product sales and adjusted EBITDA, projecting ranges of $108 million to $123 million for net sales and $10 million to $19 million for adjusted EBITDA. In Q1 2025, Assertio reported net product sales of $26 million, slightly above their plan, with Rolvedon sales at $13.1 million and Sympazan prescriptions increasing by 6.5% year-over-year. Indocin sales were stable, though impacted by generic competition with sales at $5.5 million. The gross margin increased to 70% from 65% the previous year, and the company ended the quarter with cash and investments totaling $87.3 million. Assertio's strategy includes reducing legal exposure, simplifying corporate structure, and divesting non-core assets, which they aim to complete by the end of 2025 as part of their transformation phase.Slightly Ahead of Plan for Net Product Sales
Net product sales in the first quarter came in slightly ahead of plan at $26 million, and the company is tracking to their full-year net product sales and adjusted EBITDA outlook.
Strong Rolvedon Demand and Expanded Payer Coverage
Rolvedon results were impacted by sell-through of initial stocking activity supporting customer and volume expansion, with expectations for increased net sales and expanded payer coverage starting with Cigna.
Sympazan Prescription Growth
Sympazan prescriptions increased by 6.5% year-over-year, indicating a positive trend expected to continue.
Successful Legal Settlements
Settled multiple prior legal matters and reduced legal exposure, including a significant Department of Justice False Claims Act lawsuit and Glumetza antitrust action.
Simplified Corporate Structure
Simplified corporate holding structure by transferring assets to ATIH Industries LLC, thereby reducing legal liabilities, including opioid litigation.
ASRT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
ASRT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 12, 2025 | $0.62 | $0.61 | -1.61% |
Mar 12, 2025 | $0.78 | $0.72 | -7.69% |
Nov 11, 2024 | $0.92 | $0.85 | -7.61% |
Aug 07, 2024 | $1.23 | $1.08 | -12.20% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Assertio Therapeutics Inc (ASRT) report earnings?
Assertio Therapeutics Inc (ASRT) is schdueled to report earning on Jul 31, 2025, TBA Not Confirmed.
What is Assertio Therapeutics Inc (ASRT) earnings time?
Assertio Therapeutics Inc (ASRT) earnings time is at Jul 31, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ASRT EPS forecast?
ASRT EPS forecast for the fiscal quarter 2025 (Q2) is -0.08.